299 related articles for article (PubMed ID: 24700803)
1. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples.
Riester M; Wei W; Waldron L; Culhane AC; Trippa L; Oliva E; Kim SH; Michor F; Huttenhower C; Parmigiani G; Birrer MJ
J Natl Cancer Inst; 2014 Apr; 106(5):. PubMed ID: 24700803
[TBL] [Abstract][Full Text] [Related]
2. A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer.
Cheon DJ; Tong Y; Sim MS; Dering J; Berel D; Cui X; Lester J; Beach JA; Tighiouart M; Walts AE; Karlan BY; Orsulic S
Clin Cancer Res; 2014 Feb; 20(3):711-23. PubMed ID: 24218511
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Optimal Cytoreductive Surgery of Serous Ovarian Cancer With Gene Expression Data.
Abdallah R; Chon HS; Bou Zgheib N; Marchion DC; Wenham RM; Lancaster JM; Gonzalez-Bosquet J
Int J Gynecol Cancer; 2015 Jul; 25(6):1000-9. PubMed ID: 26098088
[TBL] [Abstract][Full Text] [Related]
4. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas.
Birrer MJ; Johnson ME; Hao K; Wong KK; Park DC; Bell A; Welch WR; Berkowitz RS; Mok SC
J Clin Oncol; 2007 Jun; 25(16):2281-7. PubMed ID: 17538174
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of an immune gene-set based Prognostic signature in ovarian cancer.
Shen S; Wang G; Zhang R; Zhao Y; Yu H; Wei Y; Chen F
EBioMedicine; 2019 Feb; 40():318-326. PubMed ID: 30594555
[TBL] [Abstract][Full Text] [Related]
6. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
[TBL] [Abstract][Full Text] [Related]
7. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.
Kang J; D'Andrea AD; Kozono D
J Natl Cancer Inst; 2012 May; 104(9):670-81. PubMed ID: 22505474
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
[TBL] [Abstract][Full Text] [Related]
9. Gene expression signature with independent prognostic significance in epithelial ovarian cancer.
Spentzos D; Levine DA; Ramoni MF; Joseph M; Gu X; Boyd J; Libermann TA; Cannistra SA
J Clin Oncol; 2004 Dec; 22(23):4700-10. PubMed ID: 15505275
[TBL] [Abstract][Full Text] [Related]
10. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays.
Berchuck A; Iversen ES; Lancaster JM; Dressman HK; West M; Nevins JR; Marks JR
Am J Obstet Gynecol; 2004 Apr; 190(4):910-25. PubMed ID: 15118612
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets.
Yoshihara K; Tajima A; Yahata T; Kodama S; Fujiwara H; Suzuki M; Onishi Y; Hatae M; Sueyoshi K; Fujiwara H; Kudo Y; Kotera K; Masuzaki H; Tashiro H; Katabuchi H; Inoue I; Tanaka K
PLoS One; 2010 Mar; 5(3):e9615. PubMed ID: 20300634
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma.
Tang Z; Ow GS; Thiery JP; Ivshina AV; Kuznetsov VA
Int J Cancer; 2014 Jan; 134(2):306-18. PubMed ID: 23825028
[TBL] [Abstract][Full Text] [Related]
13. MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma.
Yu X; Zhang X; Bi T; Ding Y; Zhao J; Wang C; Jia T; Han D; Guo G; Wang B; Jiang J; Cui S
Tumour Biol; 2013 Dec; 34(6):3501-8. PubMed ID: 23836287
[TBL] [Abstract][Full Text] [Related]
14. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
15. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer.
Tucker SL; Gharpure K; Herbrich SM; Unruh AK; Nick AM; Crane EK; Coleman RL; Guenthoer J; Dalton HJ; Wu SY; Rupaimoole R; Lopez-Berestein G; Ozpolat B; Ivan C; Hu W; Baggerly KA; Sood AK
Clin Cancer Res; 2014 Jun; 20(12):3280-8. PubMed ID: 24756370
[TBL] [Abstract][Full Text] [Related]
16. Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer.
Chien J; Fan JB; Bell DA; April C; Klotzle B; Ota T; Lingle WL; Gonzalez Bosquet J; Shridhar V; Hartmann LC
Gynecol Oncol; 2009 Jul; 114(1):3-11. PubMed ID: 19410283
[TBL] [Abstract][Full Text] [Related]
17. Prediction of chemo-response in serous ovarian cancer.
Gonzalez Bosquet J; Newtson AM; Chung RK; Thiel KW; Ginader T; Goodheart MJ; Leslie KK; Smith BJ
Mol Cancer; 2016 Oct; 15(1):66. PubMed ID: 27756408
[TBL] [Abstract][Full Text] [Related]
18. Comparison between serous and non-serous ovarian cancer as a prognostic factor in advanced epithelial ovarian carcinoma after primary debulking surgery.
Hosono S; Kajiyama H; Mizuno K; Sakakibara K; Matsuzawa K; Takeda A; Kawai M; Nagasaka T; Kikkawa F
Int J Clin Oncol; 2011 Oct; 16(5):524-32. PubMed ID: 21431342
[TBL] [Abstract][Full Text] [Related]
19. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.
Yoshihara K; Tsunoda T; Shigemizu D; Fujiwara H; Hatae M; Fujiwara H; Masuzaki H; Katabuchi H; Kawakami Y; Okamoto A; Nogawa T; Matsumura N; Udagawa Y; Saito T; Itamochi H; Takano M; Miyagi E; Sudo T; Ushijima K; Iwase H; Seki H; Terao Y; Enomoto T; Mikami M; Akazawa K; Tsuda H; Moriya T; Tajima A; Inoue I; Tanaka K;
Clin Cancer Res; 2012 Mar; 18(5):1374-85. PubMed ID: 22241791
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
Vergote I; Coens C; Nankivell M; Kristensen GB; Parmar MKB; Ehlen T; Jayson GC; Johnson N; Swart AM; Verheijen R; McCluggage WG; Perren T; Panici PB; Kenter G; Casado A; Mendiola C; Stuart G; Reed NS; Kehoe S; ;
Lancet Oncol; 2018 Dec; 19(12):1680-1687. PubMed ID: 30413383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
